Aptamer Group Opens New Facility in United Kingdom
Aptamer’s new 18,000 ft² facility will expand the company's capacity to deliver novel binders for bioprocessing, diagnostic, and drug development.
Aptamer Group, a synthetic antibody provider, announced the opening of its new facility in York Science Park, United Kingdom, on Nov. 28, 2022. The 18,000 ft² facility is designed to increase capacity and facilitate delivery of the company's Optimer binders, next-generation aptamers that can be used as synthetic antibody alternatives. In addition to discovery and development, a portion of the new lab will be dedicated to validation and assay development.
“We are excited to move to the new purpose-developed site for Aptamer Group,” said Arron Tolley, CEO, Aptamer Group, in a company press release. “This will enable us to keep up with the increased demand for our Optimer technology and the growth of the team at our new larger lab and office facilities. This expansion will mean Aptamer is able to work on larger-scale projects that can be processed faster to support our partners with Optimers as a robust and much-needed alternative to antibodies.”
Source: Aptamer Group
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
